Objectives. In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets.
Introduction
Current guidelines for the management of PsA propose remission (REM) or at least low disease activity (LDA) as a treatment target [1, 2] . Indeed, consistent suppression of inflammation improves clinical outcomes in randomized comparisons [3] and, in particular, the effect of cumulative disease activity appears to influence not only joint damage [4] but also the cardiovascular outcome of PsA patients [5, 6] . Consequently, it seems important to assess the potential of a newly administered therapy early after its introduction to allow timely decisionmaking on its efficacy. For this purpose, the disease activity index for PsA (DAPSA) serves as a disease-specific compound measure that sums five characteristic disease activity variables [710] . Both the whole DAPSA score and its purely clinical version (cDAPSA), which omits CRP, have been validated for the use in PsA [11] , and for both indices response criteria and cut-off values to define disease activity states have been developed [12] . Importantly, the DAPSA-defined REM and LDA states have recently been shown to be valid against long-term functional and radiographic outcomes [13] .
The availability of parameters to predict response in PsA therapy is very limited; there is evidence from observational data that CRP [14] and ESR [14, 15] as well as male sex [15] predict achievement of minimal disease activity in patients treated with TNF-a inhibitors (TNFi). However, there is a lack of information specifically about the right point in time for the evaluation of core set variables and compound scores to make important treatment decisions and pursue long-term therapeutic targets for PsA patients. Following a treat-to-target approach, the crucial question is what a specific state or response at 3 months means with regard to the chance of achieving the recommended treatment target after 6 months. The implications for decision-making would be to change therapy at 3 months in patients who did not show sufficient improvement (or a sufficiently low state), whereas in those patients who are showing sufficient response, therapy might be continued. The aim of the present study was to analyse the predictive value of disease activity levels and, in particular, changes of disease activity (measured by the continuous DAPSA and cDAPSA) early after the start of therapy with respect to longer-term treatment success to inform clinical decision-making.
Methods

Patients
For our main analyses, we were provided with a random 90% dataset of patient-level data from the GO-REVEAL trial [16] . This large randomized controlled clinical trial evaluated the effectiveness of the TNFi golimumab (GOL) in PsA patients with prior non-response to conventional synthetic DMARDs (csDMARDs) or NSAIDs. Patients with three or more swollen and tender joints were randomly assigned to either 50 or 100 mg GOL, or placebo. In our analyses, we used data from the active treatment groups, merging the two GOL arms, and included all patients in whom DAPSA at baseline (BL), 3, 6 and 12 months was available.
Likewise, we received a random 80% dataset of the IMPACT 2 [17] trial, an randomized controlled clinical trial that investigated the effectiveness of another TNFi, infliximab, in PsA patients to validate the findings from GO-REVEAL patients externally. In IMPACT 2, patients were required to have five or more swollen and tender joints and either CRP values of 515 mg/l, ESR 528 mm/1 h and/or morning stiffness of 545 min to receive either infliximab or placebo [17] . Both clinical trials were approved by respective local ethics committees; no additional ethical approval was required for the present study.
Disease activity assessment
For all analyses, we used the DAPSA, a score that is based on the summation of five variables: number of tender 68 and swollen 66 joints, patient global assessment and patient pain assessment on a 10 cm visual analog scale, as well as CRP (in milligrams per decilitre). The DAPSA score was originally developed for ReA [18] and has recently been validated for the use in PsA [11] .
Analyses
DAPSA values as tests for subsequent DASPA states
We used a diagnostic testing approach to assess the areas under the receiver operating characteristic (ROC) curves of DAPSA values at baseline, 3 and 6 months and of early DAPSA changes regarding the achievement of a desired outcome, that is, REM or LDA after 6 months and after 1 year. Unless otherwise indicated, from now on, LDA also includes REM. An area under the ROC curve of one represents a perfect test, and an area of 0.5 a test no better than random prediction, with one misclassification for each accurate classification.
Estimating probabilities of outcomes
For guidance in clinical practice and to derive a more comprehensible everyday tool, we perfomed logistic regression analyses to model the probability of achieving at least LDA (i.e. a DAPSA 414) at 6 months depending on DAPSA levels at baseline, and after 3 months, and depending on change from baseline to 3 months in DAPSA scores. We also estimated the probability for LDA at the later 1-year assessment using baseline, 3-and 6-month DAPSA levels as well as the 3-and 6-month percentage response. Our rationale for these analyses was that prediction using 6-month data is specifically relevant in the context of the treat-to-target approach, and prediction of 1-year disease activity is important for a long-term therapeutic perspective.
The interpretation of CIs regarding statistical significance needs to be drawn with caution, as there is no formal adjustment for multiple testing. For formal statistical testing without repeated testing in one model, we provide the more complex longitudinal analysis (see below Longitudinal model and in the supplementary data, available at Rheumatology online).
Tracking back of disease activity in remitters and non-remitters
We then identified disease activity states of DAPSA at 6 months and 1 year (representing the long-term outcome of therapy). To this end, we applied the established DAPSA cut points of 44 for REM, >4 and 414 for LDA, >14 and 428 for moderate disease activity (MDA), and >28 for high disease activity (HDA) [12] . We stratified patients according to their 6-month disease activity outcome (REM, LDA, MDA or HDA) and descriptively tracked their disease activity levels back to the respective baseline values. We repeated this exercise according to the 1-year states.
Longitudinal model
To supplement our main analyses, we developed a longitudinal statistical model to predict DAPSA states after treatment in PsA. We used a generalized estimation equation with independent covariance structure. For the sake of conciseness and clarity, we present the methodology and results of the longitudinal model, which were fully confirmative of our main analyses, in the Methods section of the supplementary data, available at Rheumatology online.
cDAPSA In addition to the analyses focusing on the full DAPSA score, we evaluated the early predictive value of the purely clinical cDAPSA. In this case, we used disease activity cut points of 44 for REM, >4 and 413 for LDA, >13 and 427 for MDA and >27 for HDA, as previously described [12] . All cDAPSA results are presented in the Results section of the supplementary data, available at Rheumatology online. We used SAS statistical software (Version 9.4) for all our analyses.
Results
Patient characteristics and treatment outcomes
Including all patients who had DAPSA available at BL and 3, 6 and 12 months, we analysed a total of 216 patients from the GOL arm of the GO-REVEAL trial. Baseline characteristics are presented in Table 1 ; briefly, 40.7% were female, with a mean (S.D.) disease duration of 7.7 (7.5) years. Mean DAPSA at baseline amounted to 48.0 (26.7) and, according to the DAPSA classification [12] , 0, 2.3, 20.8 and 76.9% of patients were in REM, LDA, MDA and HDA, respectively (supplementary Table S1 , available at Rheumatology online). For external validation, we included 64 patients from IMPACT 2 and found very similar results (Table 1; Supplementary Table S1 , available at Rheumatology online).
DAPSA levels early after treatment initiation are excellent tests for the achievement of good outcomes at later assessments Disease activity levels at different time points during follow-up showed excellent properties as a test for the subsequent achievement of good outcomes. Threemonth disease activity levels were very strong predictors of LDA at 6 months, with an area under the ROC curve (AUC; and 95% CIs) of 0.92 (0.89, 0.96; Fig. 1A) . Also, early relative change between BL and 3 months was a good predictor for an LDA status at 6 months (AUC 0.84; 95% CI: 0.79, 0.89; Early treatment response is indicative of achieving good outcomes at later time points
Using logistic regression analysis, we estimated the chances for a beneficial outcome according to early Columns specify patients included in the active treatment arms of GO-REVEAL and IMPACT 2 trials and pooled data of treatment groups in both trials. Numbers specify the mean (S.D.). NA: not applicable; VAS: visual analog scale.
relative DAPSA changes and disease activity levels at 3 months. Figure 2 illustrates that, to predict the achievement of the 6-month target of LDA reliably, substantial changes of DAPSA need to be seen at 3 months ( Fig. 2A and C) , and, likewise, considerable changes at the 3-month assessment are needed in order to achieve a reasonably high probability of a good outcome at 1 year ( Fig. 2B and D) . To achieve a sufficiently high probability of reaching a good outcome at 1 year, about the same changes in DAPSA are required at 3 and at 6 months (Fig. 2D) . In other words, the predictive capacity at 3 months is not worse than at 6 months. Looking at absolute DAPSA levels among patients who achieved moderate disease activity (DAPSA >14 and 428) after 3 months of therapy, the estimated probability of achieving at least LDA at 6 months was up to 69.8%, and patients with LDA at 3 months had an estimated probability for staying in LDA or reaching REM at 6 months of 7090% (Fig. 2A) . Achievement of a 50 or 75% response in DAPSA (DAPSA50, DAPSA75) at 3 months implied at least 50 or 73% probability of LDA or REM, respectively, and DAPSA85 even a probability of >80% for a good outcome at 6 months (Fig. 2C) . Achieving DAPSA 414 (LDA) after 3 months led to an estimated probability of 578% for continuing to be in LDA (or REM) also after 1 year (Fig. 2B) , and a DAPSA75 response from baseline to 3 months predicted >80% probability for at least LDA after 1 year (Fig. 2D) . Validation analyses using IMPACT 2 data confirmed these results (supplementary Fig. S2 , available at Rheumatology online).
Tracking back patients who achieved different states at 6 months and 1 year: early differences in DAPSA levels Mean disease activity improved on TNFi very well over time, leading to a total of 39.9 and 47.5% of patients in at least LDA at 3 and 6 months, respectively (supplementary Table S1 , available at Rheumatology online). At the end of follow-up after 1 year, 30.1% of patients were in REM, 28.7% in LDA, 22.2% in MDA and 19.0% in HDA (Table S1 , available at Rheumatology online). shows that patients who achieve different DAPSA states at 6 months clearly differ at the group level already at the 3-month assessment (P 4 0.0001). In addition, there were differences in baseline values at the group level, which emphasize that the starting level of disease activity is also an important determinant of the ability to reach a good outcome. Again, validation in the IMPACT 2 dataset was confirmatory (supplementary Fig. S3 , available at Rheumatology online).
Longitudinal analysis of DAPSA in relationship to treatment targets All data on longitudinal analyses using different models and statistical approaches are shown in supplementary  Tables S2 and S3 and Figures S4S7, available at Rheumatology online. Importantly, all these analyses using more complex statistical approaches fully confirmed the predictive capacity of DAPSA at 3 months for subsequent outcomes.
Validation analyses
The analyses presented above used data of the GO-REVEAL trial. External validation using the IMPACT 2 dataset led to consistent results (supplementary Figs S1S3 and supplementary S7, available at Rheumatology online). In addition, internal validation of the longitudinal model using two different resampling methods in the GO-REVEAL dataset confirmed the presented model results (see supplementary Table S2 , available at Rheumatology online, for estimates and CIs, and supplementary Figs S5 and S6, available at Rheumatology online). Finally, we supplemented our ROC results with one analysis using the outcome ACR70 response after 6 months and 1 year as the dependent variable, in contrast to the DAPSA-based analyses in the rest of the manuscript. Here, DAPSA levels at 3 and 6 months, but not baseline DAPSA, could predict 6-month and 1-year ACR70 response (see supplementary Fig. S8 , available at Rheumatology online).
Analyses of cDAPSA
We performed all described analyses also for the cDAPSA, the clinical version of the full DAPSA, which does not include CRP. We found remarkably similar results to the data presented for DAPSA. Detailed results of the cDAPSA analyses are provided in supplementary   FIG. 2 Probabilities of achieving low disease activity at 6 months or 1 year Predicted probabilities are shown for achieving at least LDA at 6 months (A and C) or 1 year (B and D) depending on DAPSA values at baseline, 3 and 6 months (A and B) or depending on DAPSA relative change from baseline to 3 or to 6 months (C and D). Data of patients included in the GO-REVEAL treatment arm (n = 216). DAPSA: disease activity index for PsA; LDA: low disease activity. Table S1 and supplementary Figs S9 and S10, available at Rheumatology online.
Discussion
In PsA management, prompt evaluation of newly implemented medication is important to avoid losing time on therapies that may not have the potential to reduce disease activity sufficiently in the individual patient. Given the fact that an increasing number of highly efficacious treatment options are available, any state other than LDA or REM should induce a change in therapy, because delay will have consequential effects of the cumulative inflammatory burden [3, 5, 6] .
In this respect, a therapeutic evaluation at an early point in time should be attempted. Although response rates are increasing throughout the course of the whole first year of therapy, as evidenced by clinical trial data, the question arises about the minimal observation time that is required to estimate reliably the longer-term disease activity outcomes of the individual patient. According to the treat-totarget algorithm [1] , this time frame has been proposed to be 3 months for improvement and 6 months for attaining the target. Indeed, in the present study the time between the 3-and 6-month assessments brought only limited additional information for the 1-year disease activity state. Moreover, when we simply tracked back disease activity levels of patients who had reached REM, LDA, MDA or HDA, it was apparent that disease activity at 3 months was already highly predictive of a good or poor outcome at 6 months and at 1 year; similar to what has been observed in RA [19] .
In observational studies, factors that predict minimal disease activity in PsA have been explored, and there was evidence for male sex as well as CRP and ESR [14, 15] predicting favourable outcomes after TNFi treatment. However, minimal disease activity is a state, whereas the novelty of our analyses lies in the use of a continuous scale for PsA that can be used for predicting achievement of a disease state before a particular state is reached and in the identification of specific time points that serve in the process of clinical decision-making early after initiation of treatment. This enables the clinician to ascertain the likelihood of long-term therapeutic success. We show that the potential of a new therapy to suppress disease activity sufficiently at 6 months or 1 year can be predicted well at the 3-month time point, depending on whether or not patients prove to be responding at this early assessment. Consequently, treatment adaptions should be considered on this occasion. For our study, we used the DAPSA to define disease activity and categorize disease activity states. This score has previously been validated as a measure of PsA disease activity and is associated with functional and structural outcomes [8, 11, 20] . As such, it is a continuous outcome measure not only for the purpose of clinical management of PsA patients, but also serves outcomes research in the field of PsA, similar to the way that continuous scores have facilitated RA research over the past decade. Similar to previous findings in RA [19, 21] , our results indicate that treatment success in PsA is highly predictable early after start of therapy by evaluating disease activity and, in particular, the change in disease activity after the start of therapy. Importantly, and in accordance with the treat-to-target recommendations, the presence of major DAPSA responses (DAPSA75, DAPSA85) is informative about whether a patient requires treatment modifications, or whether a therapy should be continued for at least an additional 3 months. Specifically, our prediction models indicate that relatively high response rates need to be observed at the 3-month assessment, in order to justify confidence in reaching the target state upon treatment continuation for another 3 months. These findings substantiate the call for an early appraisal of any new therapy, as has been formulated in therapeutic guidelines [1] , to allow timely reaction with therapeutic adaptations in those who do not meet the desired level of improvement.
Limitations to our analyses include the lack of follow-up data overseeing an even longer time span than 1 year. This was inherent to the use of data from clinical trials, which in our case had only 1 year of treatment with a single compound. Nevertheless, 3-and 6-month levels predicted 1-year outcomes in a similar manner, suggesting that a longer observation period would not necessarily provide additional clinically relevant information. The prediction model might differ slightly according to the mode of action of the drug used, which in our case were two TNFi.
The DAPSA lacks enthesitis and dactylitis assessment, as well as skin involvement, for which separate validated instruments exist. The controversy regarding how to construct scores for the assessment of PsA has been discussed broadly at the recent international meeting that validated the treat-to-target approach for spondyloathritis, including PsA; indeed, DAPSA was one of the endorsed tools for follow-up of patients with PsA [1] . In line, we recently showed that patients who achieved DAPSA REM on a TNFi also had minimal enthesitis and dactylitis as well as Psoriasis Area and Severity Index scores, which did not differ from the very LDA state; likewise, DAPSA LDA conveyed similar non-articular outcomes to MDA [22] . Given the available core set variables in trial data, we show that achieving at least LDA in PsA can be predicted based on the parameters included in the DAPSA. The strength of the present study lies in the availability of patient-level data from two large randomized controlled clinical trials that investigated two of the most frequently used biologics in PsA therapy.
Outcome measures in clinical trials are consistently evaluated by trained assessors, which is highly valuable for studies like the present one. We found very similar results in the two different trials, inherently validating the data presented. Finally, we consider the consistency of different methods addressing the same question as highly confirmatory. These methods included a diagnostic testing approach, which integrates sensitivity and specificity into the investigated association, and more advanced regression modelling, which is useful for clinicians estimating risks and benefits for their patients.
In summary, our study demonstrates that the initial response to PsA therapy holds a highly significant predictive value and predicts long-term outcomes as early as 3 months after initiation of treatment. Thus, our results further support treatment algorithms in their demand for timely adaptations and provide guidance for rheumatologists who apply such strategies, as to whether and when adaptations are justified and, even more importantly, highly required. Our study provides some numerical guidance for the treating rheumatologists to quantify the probability of reaching the therapeutic target in their patients after specific disease activity states and amounts of change from baseline.
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